Market capitalization | $630.35m |
Enterprise Value | $593.33m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.24 |
P/S ratio (TTM) P/S ratio | 3.44 |
P/B ratio (TTM) P/B ratio | 8.51 |
Sales growth (TTM) Sales growth | -16.91% |
Turnover (TTM) Turnover | $183.23m |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
16 Analysts have issued a Travere Therapeutics Inc forecast:
16 Analysts have issued a Travere Therapeutics Inc forecast:
Mar '24 | |
Current assets | 481 481 |
Fixed assets | 182 182 |
Total assets | 664 664 |
Mar '24 | |
Equity | 74 74 |
Debt capital | 589 589 |
Total capital | 664 664 |
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.
Head office | United States |
CEO | Eric Dube |
Employees | 380 |
Founded | 2008 |
Website | www.travere.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.